SCHEMBL2375754

SCHEMBL2375754

COCCN(C)C(=O)C(Cc1ccccc1)N(Cc1ccc(-c2ccncc2)cc1)C(=O)C=Cc1ccc(C(F)(F)F)cn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR5A P47898 2/20 0.42
GPR119 Q8TDV5 2/20 0.41
SCN9A Q15858 2/20 0.38
GHSR Q92847 1/20 0.37
LIPE Q05469 1/20 0.37
CASR P41180 1/20 0.36
MTTP P55157 2/20 0.35
HIF1A Q16665 1/20 0.35
EPAS1 Q99814 1/20 0.35
ITGB1 P05556 1/20 0.35
ITGA4 P13612 1/20 0.35
MME P08473 1/20 0.35
NOS3 P29474 1/20 0.35
NOS1 P29475 1/20 0.35
NOS2 P35228 1/20 0.35
HTR1A P08908 1/20 0.35
DRD2 P14416 1/20 0.35
DRD4 P21917 1/20 0.35
HTR1D P28221 1/20 0.35
HTR1B P28222 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2375745 1.00 HTR5A (0.42) HTR5AGPR119SCN9AGHSRLIPE
SCHEMBL2375748 1.00 HTR5A (0.42) HTR5AGPR119SCN9AGHSRLIPE
SCHEMBL2373755 0.95 HTR5A (0.39) HTR5AGPR119SCN9AGHSRLIPE
SCHEMBL2373753 0.95 HTR5A (0.39) HTR5AGPR119SCN9AGHSRLIPE
SCHEMBL2373758 0.95 HTR5A (0.39) HTR5AGPR119SCN9AGHSRLIPE
SCHEMBL2374026 0.93 GPR119 (0.38) HTR5AGPR119SCN9AGHSRLIPE
SCHEMBL2374021 0.93 GPR119 (0.38) HTR5AGPR119SCN9AGHSRLIPE
SCHEMBL2374024 0.93 GPR119 (0.38) HTR5AGPR119SCN9AGHSRLIPE
SCHEMBL2337324 0.89 HTR5A (0.39) HTR5AGPR119GHSRMME
SCHEMBL2337317 0.89 HTR5A (0.39) HTR5AGPR119GHSRMME

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110224210-A1 NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS ACTELION PHARMACEUTICALS LTD. (CH) 2011-09-15 US claimed
US-20110224210-A1 NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS ACTELION PHARMACEUTICALS LTD. (CH) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224210-A1 NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS CTSA, BECN1, HDAC6 HTR5A 4420/4885GPR119 2204/4885SCN9A 3807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.